High levels of TMB have been shown to correlate with increased responsiveness of non-small-cell lung cancer to immune checkpoint inhibitors nivolumab and ipilimumab [10] and of malignant melanoma to anti-CTLA-4 antibody treatment [11]. The gene discussed is CTLA4; the disease is non-small cell lung carcinoma.